Platelet imipramine binding is increased in essential thrombocythaemia

Platelet‐rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV‐1 assay

“…Decreased intra‐platelet serotonin content is a well‐recognized phenomenon in CMPD (Pareti et al , 1982). The mechanism, although looked into in the past (Castaldi et al , 1982; Caranobe et al , 1984; Cortellazzo et al , 1985; Leoncini et al , 1990; Jackson et al , 1992), has not been completely elucidated. The results of the limited studies that are available in this regard are conflicting.…”

“…The results of the limited studies that are available in this regard are conflicting. While some of these studies suggest a reduced number of serotonin‐binding sites (Caranobe et al , 1984), others have demonstrated normal uptake kinetics of the biological amine (Cortellazzo et al , 1985) and increased imipramine‐binding sites on the platelets of patients with CMPD (Jackson et al , 1992). Regardless, the current study revealed a significant degree of variation in the extent of the particular platelet defect among the three CMPD variants.…”

“…The content of these dense bodies, including that of serotonin, has been shown to be decreased in patients with CMPD (Pareti et al , 1982). The mechanism of this phenomenon remains undefined but possibilities include decreased amine uptake, inefficient storage and abnormal release (Caranobe et al , 1984; Cortellazzo et al , 1985; Jackson et al , 1992). Various laboratory methods to measure intra‐platelet serotonin content are currently available and include high‐performance liquid chromatography, radioimmunoassay, ELISA, and fluorescence‐based immunocytochemical assay (Gow et al , 1987; Chauveau et al , 1991; Keating et al , 1993; Maurer‐Spurej et al , 2002).…”